NRSN

NeuroSense Therapeutics (NRSN)

About NeuroSense Therapeutics (NRSN)

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Details

Daily high

$1.23

Daily low

$1.17

Price at open

$1.21

52 Week High

$2.60

52 Week Low

$0.81

Market cap

35.5M

Dividend yield

0.00%

Volume

56,040

Avg. volume

400,451

P/E ratio

-2.05

NeuroSense Therapeutics News